Home/ Stocks/ QNCX

Quince Therapeutics, Inc. Common Stock

QNCX XNAS

$0.09 -0.01 (-9.45%) ▼ 15-min delayed

Open

$0.09

High

$0.10

Low

$0.09

Volume

8.54M

Market Cap

$5.66M

About Quince Therapeutics, Inc. Common Stock

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 36 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-13,488,000	$-0.25
Q2 2025	$0	$-15,982,000	$-0.34
Q1 2025	$0	$-15,030,000	$-0.34
FY 2024	$0	$-56,828,000	$-1.31

Related Market News

No specific coverage for QNCX yet. Check out our latest market news or earnings calendar.

Get QNCX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Quince Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.